Camrelizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Camrelizumab
DrugBank Accession Number
DB14776
Background

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Type
Biotech
Groups
Investigational
Synonyms
  • Camrelizumab
External IDs
  • SHR-1210
  • SHR1210

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UProgrammed cell death protein 1
inhibitor
antibody
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Camrelizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Camrelizumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Camrelizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Camrelizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Camrelizumab.
AmivantamabThe risk or severity of adverse effects can be increased when Camrelizumab is combined with Amivantamab.
AnsuvimabThe risk or severity of adverse effects can be increased when Camrelizumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Camrelizumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Camrelizumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Camrelizumab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
73096E137E
CAS number
1798286-48-2

References

General References
Not Available
Wikipedia
Camrelizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentChemotherapy Effect / Lung Cancer Squamous Cell / Lung carcinoma cell type unspecified stage IV / PD-1 Antibody1
3Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
3CompletedTreatmentCarcinoma, Bronchogenic / Chronic Lung Diseases / Neoplasm, Bronchial / Neoplasms by Site / Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC) / Respiratory Tract Diseases / Respiratory Tract Neoplasms / Thoracic Neoplasms1
3CompletedTreatmentEsophageal Carcinoma1
3Not Yet RecruitingTreatmentEsophageal Malignant Neoplasm, Local Recurrence1
3Not Yet RecruitingTreatmentHepatocellular Carcinoma (HCC)1
3Not Yet RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3Not Yet RecruitingTreatmentPancreatic Cancer Metastatic / Pancreatic Cancer Stage IV1
3Not Yet RecruitingTreatmentPD-L1 Positive Non-small Cell Lung Cancer1
3RecruitingTreatmentAdvanced Esophageal Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Antibody
General Function
Signal transducer activity
Specific Function
Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. ...
Gene Name
PDCD1
Uniprot ID
Q15116
Uniprot Name
Programmed cell death protein 1
Molecular Weight
31646.635 Da

Drug created on May 20, 2019 14:26 / Updated on February 21, 2021 18:54